Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma
Kotaro Hirashima(Kumamoto University), Hideo Baba(Kaketsuken (Japan))
Cited by 47
Related Papers
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
|Nature Medicine|2018|317
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
|Nature Medicine|2018|282
Long‐term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: a multi‐institutional Japanese study
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|267